|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.068 AUD | +6.25% |
|
-6.85% | +15.25% |
| Feb. 28 | Percheron Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| 2023 | Dimerix Appoints Nonexecutive Chair | MT |
Antisense Therapeutics Limited reported earnings results for the full year ended June 30, 2023. For the full year, the company reported revenue was AUD 1.96 million compared to AUD 1.81 million a year ago. Net loss was AUD 11.38 million compared to AUD 5.81 million a year ago.
Basic loss per share from continuing operations was AUD 0.017 compared to AUD 0.0092 a year ago. Diluted loss per share from continuing operations was AUD 0.017 compared to AUD 0.0092 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +15.25% | 39.98M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
PERCHERON THERAPEUTICS LIMITED 
